

106. (Twice Amended) A method of introducing protein in a mammal which comprises delivering to a blood vessel in the mammal a transformed vascular cell, the transformed cell originating from the mammal or being syngeneic to the mammal and comprising an exogenous nucleic acid encoding the protein and competent to express the protein when implanted in the mammal.

107. (Amended) The method of claim 106 wherein the transformed cell becomes attached to the wall of the vessel in the mammal.

108. (Amended) The method of claim 106 wherein the transformed cell is an endothelial cell or a smooth muscle cell.

115. (Twice Amended) A method of treating a human patient comprising the step of site-specific instillation of cells into the patient, wherein the cells originate from the patient or are syngeneic to the patient and are selected from the group consisting of endothelium, smooth muscle, and parenchymal cells.

120. (Amended) The method of claim 116, wherein the protein is a gene product of a marker gene.

#### Remarks

Applicants would like to thank Examiner Wehbé for the courteous and helpful discussions on July 11, 2002. Claims 106-108, 115 and 120 are amended herein, in accordance with the amendments discussed with the Examiner on July 11, 2002.

Claims 106-108 and 115 have been amended to replace the term "transfected" with the term "transformed." Support for this amendment may be found, for example, at page 20, lines 12-14, of the specification. Dependent claims 107 and 108 have also been amended to clarify that the cells encompassed by the claims are "transformed" cells.